Alzheimer's disease Diagnosis and Plasma phospho-tau217 - the ADAPT study - Dr Ashvini Keshavan (UCL)

This video is the 8th talk from our Future Blood Testing: Webinar 2024 series. Bio: Dr Ashvini Keshavan is a senior clinical research fellow and honorary consultant neurologist at the Dementia Research Centre, UCL Queen Square Institute of Neurology. A graduate of Trinity College, Cambridge, she completed postgraduate neurology training in London, and obtained her PhD in 2019 on Cerebrospinal fluid and blood biomarkers of Alzheimer’s disease. Her ongoing work examines these biomarkers in clinical and pre-clinical cohorts, aiming toward future application in more real-world settings, serving diverse populations. She is the joint primary investigator for the UK-wide ADAPT (Alzheimer’s disease Diagnosis and Plasma p-Tau217) study. Abstract: Exciting progress is being made in the early and accurate detection of Alzheimer’s disease (AD) using blood tests. The most promising of these blood markers is plasma p-tau217. I will first review the evidence for concordance of plasma p-tau217 with gold standard Alzheimer’s disease biomarkers (i.e. amyloid positron emission tomography and cerebrospinal fluid tests) and the current state of commercial availability of plasma phosphorylated tau biomarkers including comparisons of effect sizes. I will then proceed with describing the plan for ADAPT, a three-stage study including a UK multi-centre randomised controlled trial of disclosure of plasma p-tau217 results to patients and clinicians. From this study we aim to find out whether plasma p-tau217 helps to diagnose AD more quickly, more accurately and at an earlier disease stage in comparison to routine memory clinic diagnostic pathways, and we will obtain evidence for its cost effectiveness and acceptability to patients. Ashvini Keshavan receives funding from the Alzheimer’s Association, the NIHR i4i programme (co-investigator - DIADEM), the LifeArc Translation award and the Blood Biomarker Challenge grant which funds the ADAPT study (Alzheimer’s Research UK, Alzheimer’s Society, National Institute for Health Research, People’s Postcode Lottery, Postcode Dream Fund, Gates Ventures). She is the co-chair of the Real World Translation Work Group and an executive committee member for the Biofluid Biomarkers Professional Interest Area of the Alzheimer’s Association. Further details on this event can be found at: Democratising Healthcare Technology: The Role and Challenges of Participatory Design in Healthcare (futurebloodtesting.org) Further details on the full webinar series can be found here: https://futurebloodtesting.org/events/future-blood-testing-webinar-series/ YouTube Link: Democratising Healthcare Technology: The Role and Challenges of Participatory Design in Healthcare (youtube.com) This video is an output from the Future Blood Testing Network which is funded by EPSRC under Grant Number EP/W000652/1